Stem Cell Reports, Volume 8

Supplemental Information

Cardiosphere-Derived Cells Require Endoglin for Paracrine-Mediated

Angiogenesis

Rachael E. Redgrave, Simon Tual-Chalot, Benjamin J. Davison, Esha Singh, Darroch Hall, Muhammad M. Amirrasouli, Derek Gilchrist, Alexander Medvinsky, and Helen M. Arthur



Figure S1 Generation of CAG-farneslylated eGFP transgenic mouse line.

A-C: The *CAG-farnesylated-eGFP* transgenic mouse line was generated using the plasmid illustrated in which the CAG promoter (open blue box) was cloned upstream of a puromycin acetyl transferase (Puro) STOP cassette (closed black box) and the coding region for farnesylated eGFP (Clontech) was cloned downstream (A). The Puro-STOP cassette was floxed by 2 wild-type loxP sites and was excised by Cre/loxP recombination in vivo by crossing with female ZP3-Cre transgenic mice, resulting in constitutive expression of farnesylated eGFP (B,C). Constitutive eGFP expression in over 92% of CDCs prepared from this line was confirmed by FACS analysis (D).





Figure S2 CDC properties of conditioned media and cell differentiation potential in vivo

A Protein concentration in conditioned media prepared from CDCs is equivalent in CM and Eng^{KO} CM. Protein concentration for each sample of CDC conditioned media (n=14) was quantified by Bradford assay.

B-C Tracking GFP labelled CDCs in recipient hearts following myocardial infarction. Rare GFP-positive CDCs from the *CAG-farnesylated-eGFP* transgenic mouse donor line were observed 4 weeks after injection. Genetically tagged GFP positive CDCs that had differentiated to express the endothelial marker CD31 (B) or the cardiomyocyte marker alpha-actinin. Scale bar=10um

Α



Figure S3 Cardiac function following myocardial infarction with and without delivery of control and *Eng*^{KO} CDCs to the infarct border zone

A,B: Left ventricular end diastolic volume (LV-EDV) and end systolic volume (LV-ESV) increases at 1 and 4 weeks following MI in adult male C57BL/6 mice. Outcomes were similar in all MI groups irrespective of whether PBS, control CDCs or Eng^{KO} CDCs were delivered to the infarct border zone.

C,D: Left ventricular ejection fraction (LV-EF) is reduced whilst myocardial mass (LV-mass) increases at 1 and 4 weeks following MI in adult male C57BL/6 mice. These changes were similar in all MI groups irrespective of whether PBS, control CDCs or *Eng*^{KO} CDCs were delivered to the infarct border zone.

All data are plotted as means +/- SEM. Group sizes: Sham, N= 11; MI +PBS, N= 18; MI+CDCs, N= 11; MI+*Eng*^{KO}-CDCs, N=8.



Figure S4 Dynamic changes in expression of TGF^β family ligands following myocardial infarction.

A,B: Analysis by qPCR shows dynamic changes in expression of TGF β 1 and TGF β 3 transcripts in left ventricular free wall following myocardial infarction (MI). Transcript levels in MI and sham hearts are calculated relative to normal hearts from naive age-matched male C57BL/6 mice. TGF β 1 expression peaks in the infarcted heart tissue at day 5 following MI, whilst TGF β 3 continues to increase at day 7. Data analysis by two-way ANOVA show that MI caused a significant increase in TGF β 1 and TGF β 3 expression. Post hoc t tests were corrected for multiple comparisons; *p<0.05 (n=6/group). **C-E:** ELISA of mouse serum shows concentration of circulating TGF β 1, BMP9 and BMP10 protein following myocardial infarction or sham surgery. Circulating protein levels are calculated relative to those from naive age-matched male C57BL/6 mice. Data was analysed by two-way ANOVA and circulating levels of BMP9 showed significant decrease whilst BMP10 showed significant increase following surgery. Post hoc t tests were corrected for multiple comparisons; *p<0.05 (n=4/group).



Figure S5 Loss of endoglin in CDCs has no effect on VEGF levels in conditioned media (CM) or on stimulation of AKT pathway in CM-treated endothelial cells .

A: Concentration of VEGF in CDC-CM is similar in control-CM and EngKO-CM, plotted as mean +/-SEM; N=15/group.

B: Treatment of HUVECs with control CM and Eng^{KO} CM for 5, 15 and 30 minutes led to similar activation of proteins downstream of VEGF signalling. Representative western blot showing phospho-AKT serine473, phospho-AKT threonine 308 and phospho-GSK levels are present at comparable levels following stimulation of HUVECs with control CM and Eng^{KO} CM, consistent with their similar VEGF content.



B Primers used for RT-PCR.

ENG	F: CAATGCCAGCATTGTCACCTCC R: AGAGGCTGTCCATGTCGATGCA
ALK1	F: GACCTTGGGGAGCTTCAGA
	R: TGCAGAAGGATCTATAGCAGCA
ALK5	F: GCACCATCTTCAAAAACAGGGG
	R: GCCAAACTTCTCCAAACCGACC
TGFBR2	F: GGAAGTCTGCGTGGCCGTGTGG
	R: CTATGGCAATCCCCAGCGGAGG
BMPR2	F: CTCAGAATCAAGAACGGCTGTG
	R: TGAATGAGGTGGACTGAGTGGT
β-Actin	F: TGAACCCTAAGGCCAACCGTG
	R: GCTCATAGCTCTTCTCCAGGG

Figure S6 Receptor components of the TGF β and BMP9 signalling pathways are present in CDCs. TGFBR2, BMPR2, ALK1 and ALK5 receptors for BMP/TGF β signalling are all expressed in control and Eng^{KO} CDCs as assessed by rtPCR (A), using primers shown (B).



Figure S7 Summary of signalling defects in CDCs in the absence of endoglin, and rescue by BMP9.

A: Wild type CDCs show activation of SMAD2/3 and SMAD1/5/8 pathways in response to exogenous ligands. Activation of these pathways is stimulated by TGF β (present in the heart and circulation) and BMP9 (present in the circulation).

B: Loss of endoglin leads to reduced activation of SMAD1/5/8 pathway but has no detectable effect on the SMAD2/3 pathway.

C: ALK5 Inhibitor (SB431542) decreases activation of the pSMAD2/3 pathway but does not restore the SMAD1/5/8 pathway.

D: BMP9 treatment rescues activation of the SMAD1/5/8 pathway, which in turn rescues the proangiogenic defects of Eng^{KO}-CM.